4Misset JL.Oxaliplatin in practice[J].Br J Cancer,1998,77 (suppl 4):4.
5Saitoh M,Taguchi k,Momose K,et al.Recombinant human interleukin-Ⅱ improved carboplatin-induce thrombocytopenia without affecting antitumor activities in mice bearing Lewis lung carcinoma cells[J].Cancer Chemother Pharmacol,2002,49 (2):161.
6Kurzrock R,Cortes J,Thomas DA,et al.Pilot study of low-dose interleukin-Ⅱ in patinets with bone marrow failure[J].J Clin Oncol,2001,19 (21):4165.
7Verweij J,van Zanten T,Souren T,et al.Prospective study on the dose relationship of mitomycin C -induce interstitial pneumonitis[J].Cancer,1987,60(4):756.
8Grolleau F,Gamelin L,Boisdron -Celle M,et al.A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels[J].J Neurophysiol,2001,85(50):2293.
9Laack E,Mende T,Knuffmann C,et al.Hand-foot syndrome associated with short infusions of combination chemotherapy with gecitabine and vinorelbine[J].Ann Oncol,2001,12 (12):1761.
10Elasmar SA,Saad ED,Hoff PM.Case report:hand-foot syndrome induced by the oral fluoropyrimidine S-1[J].Jpn Clin Onco,2001,31(4):172.
7Sean C Sweetman .Martindale:The Complete Drug Reference [M].The Pharmaceutical Press,2007:506,592,610.
8国家药典委员会.临床用药须知[M].2005版.北京:人民卫生出版社,2005:649-650.
9Cunningham D,Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinote-can in irinotecan-refractory metastatic colorectal cancer [J]. N Engl J Med, 2004, 351: 337-345.
